ESPE Abstracts

Background: Children with different growth disorders need therapy with recombinant human GH. Although mostly therapy leads to good results there are clinical cases when the therapy is not working. One of the reasons is patient’s and patient’s family’s adherence. That’s why it is necessary to explore what are the adherence and its impact on therapy’s outcome. Growth disorders can make an influence to all humans’ life, that’s why if it is possible to do something to change it must be done. It is necessary to explore the situation in Latvia so that we can make conclusions and recommendations how to improve the situation.

Objective and hypotheses: There is hypothesis to prove that children in Latvia with GH therapy have bad adherence and it impacts the therapy’s outcome.

Method: Research is still going on. It is retrospective–prospective research. Literature of the last 5–10 years has been analysed. Statistical analysis is made with material that is taken from Children Clinical University Hospital ambulatory cards after special questionnaire. Patients aged 0–18 years are included, who are on GH treatment on years 2013–2014 and uses Easypod device.

Results: As the research continues, the final results will follow.

Conclusion: Already from the first results we can conclude, that adherence to the treatment with Easypod device is quite well. We can also see that pubertal children have worse adherence than smaller children, because in pubertal period parents don’t have so big influence on therapy and the therapy is more superficially done. The research must be continued to see if in Latvian population computerized and controlled therapy really gives better results.

Abstract withdrawn.